These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 39489506)
41. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. Beck LA; Thaçi D; Hamilton JD; Graham NM; Bieber T; Rocklin R; Ming JE; Ren H; Kao R; Simpson E; Ardeleanu M; Weinstein SP; Pirozzi G; Guttman-Yassky E; Suárez-Fariñas M; Hager MD; Stahl N; Yancopoulos GD; Radin AR N Engl J Med; 2014 Jul; 371(2):130-9. PubMed ID: 25006719 [TBL] [Abstract][Full Text] [Related]
42. The anti-IL-4 receptor alpha antibody dupilumab: facing a new era in treating atopic dermatitis. Tsianakas A; Luger TA Expert Opin Biol Ther; 2015; 15(11):1657-60. PubMed ID: 26457448 [TBL] [Abstract][Full Text] [Related]
43. Dupilumab in Adults With Moderate to Severe Atopic Dermatitis: A 5-Year Open-Label Extension Study. Beck LA; Bissonnette R; Deleuran M; Nakahara T; Galus R; Coleman A; Gherardi G; Xiao J; Dingman R; Xu C; Avetisova E; Dubost-Brama A; Shabbir A JAMA Dermatol; 2024 Aug; 160(8):805-812. PubMed ID: 38985486 [TBL] [Abstract][Full Text] [Related]
44. Cyclosporine 0.1% (Ikervis Roca-Ginés J; Rahhal-Ortuño M; Torres-Navarro I; Rodríguez-Serna M; Navarro-Mira MÁ Arch Soc Esp Oftalmol (Engl Ed); 2019 Aug; 94(8):396-399. PubMed ID: 31178231 [TBL] [Abstract][Full Text] [Related]
45. Long-term, observational, real-world study of dupilumab for the treatment of moderate-to-severe atopic dermatitis: a 52-week single-center retrospective analysis in China. Deng S; Wang H; Chen Q; Chen X; Song X; Chen S; Kong M; Song Z Arch Dermatol Res; 2024 May; 316(6):304. PubMed ID: 38819652 [TBL] [Abstract][Full Text] [Related]
46. Dupilumab for atopic dermatitis: evidence to date. Rodrigues MA; Nogueira M; Torres T G Ital Dermatol Venereol; 2019 Dec; 154(6):696-713. PubMed ID: 31210470 [TBL] [Abstract][Full Text] [Related]
47. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Paller AS; Simpson EL; Siegfried EC; Cork MJ; Wollenberg A; Arkwright PD; Soong W; Gonzalez ME; Schneider LC; Sidbury R; Lockshin B; Meltzer S; Wang Z; Mannent LP; Amin N; Sun Y; Laws E; Akinlade B; Dillon M; Kosloski MP; Kamal MA; Dubost-Brama A; Patel N; Weinreich DM; Yancopoulos GD; O'Malley JT; Bansal A; Lancet; 2022 Sep; 400(10356):908-919. PubMed ID: 36116481 [TBL] [Abstract][Full Text] [Related]
48. Comparison of Old and New Systemic Treatments for Moderate to Severe Atopic Dermatitis. Yim HJ; Jean T; Ong PY Curr Allergy Asthma Rep; 2024 May; 24(5):289-301. PubMed ID: 38632138 [TBL] [Abstract][Full Text] [Related]
49. Usage and effectiveness of systemic treatments in adults with severe atopic eczema: First results of the German Atopic Eczema Registry TREATgermany. Schmitt J; Abraham S; Trautmann F; Stephan V; Fölster-Holst R; Homey B; Bieber T; Novak N; Sticherling M; Augustin M; Kleinheinz A; Elsner P; Weidinger S; Werfel T J Dtsch Dermatol Ges; 2017 Jan; 15(1):49-59. PubMed ID: 27862987 [TBL] [Abstract][Full Text] [Related]
51. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). Thaçi D; L Simpson E; Deleuran M; Kataoka Y; Chen Z; Gadkari A; Eckert L; Akinlade B; Graham NMH; Pirozzi G; Ardeleanu M J Dermatol Sci; 2019 May; 94(2):266-275. PubMed ID: 31109652 [TBL] [Abstract][Full Text] [Related]
52. Systemic treatment of children and adolescents with atopic dermatitis aged ≥2 years: a Delphi consensus project mapping expert opinion in Northern Europe. de Graaf M; Janmohamed SR; Schuttelaar MLA; Agner T; Alfonso JH; De Schepper S; Deleuran M; Despontin K; Elenius V; Ghislain PD; Huilaja L; Johansson EK; Kvenshagen BK; Mandelin JM; Olset H; Svensson A; van Tuyll van Serooskerken AM; Thyssen JP; Vestergaard C J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2153-2165. PubMed ID: 35793471 [TBL] [Abstract][Full Text] [Related]
53. Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis. Treister AD; Kraff-Cooper C; Lio PA JAMA Dermatol; 2018 Oct; 154(10):1208-1211. PubMed ID: 30167653 [TBL] [Abstract][Full Text] [Related]
54. Immunosuppressive and immunomodulating therapy for atopic dermatitis in pregnancy: an appraisal of the literature. Drljevic-Nielsen A; Heilskov S; Deleuran MS; Vestergaard C Ital J Dermatol Venerol; 2024 Feb; 159(1):23-33. PubMed ID: 38226937 [TBL] [Abstract][Full Text] [Related]
55. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. Schram ME; Roekevisch E; Leeflang MM; Bos JD; Schmitt J; Spuls PI J Allergy Clin Immunol; 2011 Aug; 128(2):353-9. PubMed ID: 21514637 [TBL] [Abstract][Full Text] [Related]
56. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972 [TBL] [Abstract][Full Text] [Related]
57. Systemic anti-inflammatory treatment of atopic dermatitis during conception, pregnancy and breastfeeding: Interdisciplinary expert consensus in Northern Europe. Deleuran M; Dézfoulian B; Elberling J; Knutar I; Lapeere H; Lossius AH; Schuttelaar MLA; Stockman A; Wikström E; Bradley M; de Bruin-Weller M; Gutermuth J; Mandelin JM; Schmidt MC; Thyssen JP; Vestergaard C J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):31-41. PubMed ID: 37818828 [TBL] [Abstract][Full Text] [Related]
58. Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. Chu AWL; Wong MM; Rayner DG; Guyatt GH; Díaz Martinez JP; Ceccacci R; Zhao IX; McMullen E; Srivastava A; Wang J; Wen A; Wang FC; Brignardello-Petersen R; Izcovich A; Oykhman P; Wheeler KE; Wang J; Spergel JM; Singh JA; Silverberg JI; Ong PY; O'Brien M; Martin SA; Lio PA; Lind ML; LeBovidge J; Kim E; Huynh J; Greenhawt M; Gardner DD; Frazier WT; Ellison K; Chen L; Capozza K; De Benedetto A; Boguniewicz M; Smith Begolka W; Asiniwasis RN; Schneider LC; Chu DK J Allergy Clin Immunol; 2023 Dec; 152(6):1470-1492. PubMed ID: 37678577 [TBL] [Abstract][Full Text] [Related]
59. Systemic treatment for severe atopic dermatitis in children: a case series. Cheirif-Wolosky O; Elizalde-Jiménez IG; Romero MTG Bol Med Hosp Infant Mex; 2022; 79(5):310-317. PubMed ID: 36264887 [TBL] [Abstract][Full Text] [Related]
60. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. Deleuran M; Thaçi D; Beck LA; de Bruin-Weller M; Blauvelt A; Forman S; Bissonnette R; Reich K; Soong W; Hussain I; Foley P; Hide M; Bouaziz JD; Gelfand JM; Sher L; Schuttelaar MLA; Wang C; Chen Z; Akinlade B; Gadkari A; Eckert L; Davis JD; Rajadhyaksha M; Staudinger H; Graham NMH; Pirozzi G; Ardeleanu M J Am Acad Dermatol; 2020 Feb; 82(2):377-388. PubMed ID: 31374300 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]